Therapeutic effect of bismuth potassium citrate combined with famotidine on peptic ulcer and its effects on lipid peroxide,malondialdehyde and somatostatin levels / 中国医师进修杂志

ABSTRACT

Objective To explore the therapeutic effect of bismuth potassium citrate combined with famotidine on peptic ulcer and its effects on the levels of lipid peroxide (LPO),malondialdehyde (MDA) and somatostatin (SS).Methods One hundred and fifty patients with peptic ulcer who were treated in Cixi Cilin Hospital from January 2018 to May 2019 were randomly divided into famotidine group and combined treatment group,with 75 cases in each group.Famotidine group was treated with famotidine,while bismuth potassium citrate combined with famotidine was used in combined treatment group.H+-K+-ATP ase activity,gastric acid-base value and gastric acid secretion function were detected in two groups.The levels of tumor necrosis factor-ot (TNF-α),interleukin-7 (IL-7),hypersensitive C-reactive protein (hs-CRP) were detected by ELISA,T lymphocyte subsets were detected by flow cytometry,and the levels of T lymphocyte subsets were detected by immunotransmission turbidimetry.The levels of LPO,MDA and SS were measured,and the therapeutic effect,ulcer healing and adverse reactions were compared between two groups.Results After treatment,the activity of H+-K+-ATP ase in the combined treatment group was lower than that in the famotidine group [(2.54 ± 0.41) μmol/min vs.(2.87 ± 0.50) μmol/min],the acid-base value in stomach was higher than that in the famotidine group (5.56 ± 1.19 vs.4.77 ± 0.89),and there were significant differences (P ＜ 0.05).After treatment,the levels of maximum gastric acid excretion after pentagastrin stimulation (MAO),peak gastric acid output (PAO),basal acid output (BAO),TNF-α,IL-17,hs-CRP,CD8+,LPO and MDA in combined treatment group were lower than those in famotidine group [(8.22 ± 1.76) mmol/h vs.(10.53 ± 2.21) mmol/h,(11.88 ± 2.51)mmol/h vs.(14.79 ± 2.76) mmol/h,(4.11 ± 1.32) mmol/h vs.(5.54 ± 1.49) mmol/h,(4.76 ± 1.52) ng/L vs.(6.91 ± 1.61) ng/L,(18.37 ± 3.25) ng/L vs.(22.83 ± 3.62) ng/L,(6.41 ± 1.81) mg/L vs.(8.67 ± 2.15) mg/L,0.287 6 ± 0.030 5 vs.0.325 5 ± 0.032 4,(0.06 ± 0.02) U/mg vs.(0.09 ± 0.03) U/mg,(10.19 ± 1.86) μmol/L vs.(13.25 ± 2.03) μmol/L],while the levels of CD3+,CD4+,SS were higher than those in the famotidine group [0.523 6 ± 0.040 9 vs.0.476 3 ± 0.039 5,0.356 6 ± 0.035 2 vs.0.315 8 ± 0.033 9,(14.59 ± 2.67)ng/L vs.(10.36 ± 2.31) ng/L],and there were significant differences (P＜0.05).The total effective rate and ulcer healing rate in combined treatment group were higher than those in famotidine group [93.33％ (70/75) vs.80.00％ (60/75),94.67％ (71/75) vs.82.67％ (62/75)] (P＜ 0.05).The incidence of adverse reactions in combined treatment group was slightly higher than that in famotidine group [16.00％(12/75)vs.13.33％ (10/75)],but there was no significant difference between the two groups (P＞0.05).Conclusions Bismuth potassium citrate combined with famotidine in the treatment of peptic ulcer patients can improve gastric acid secretion function,regulate gastric acid-base value,inhibit inflammatory response,improve immune function,and reduce oxidative stress injury.